Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) EPS (Weighted Average and Diluted) (2021 - 2025)

HeartSciences filings provide 5 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.85 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 62.56% to -$0.85 in Q4 2025 year-over-year; TTM through Oct 2025 was -$6.88, a 11.91% increase, with the full-year FY2025 number at -$9.34, up 50.16% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.85 in Q4 2025 for HeartSciences, up from -$1.58 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.11 in Q2 2024 to a low of -$79.36 in Q2 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$1.22 (2025), compared with a mean of -$6.96.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 12909.84% in 2023 and later skyrocketed 100.14% in 2024.
  • HeartSciences' EPS (Weighted Average and Diluted) stood at -$0.31 in 2021, then grew by 29.03% to -$0.22 in 2022, then plummeted by 7136.36% to -$15.92 in 2023, then surged by 85.74% to -$2.27 in 2024, then surged by 62.56% to -$0.85 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.85 (Q4 2025), -$1.58 (Q3 2025), and -$1.88 (Q2 2025) per Business Quant data.